MX2024009995A - Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la hidrosadenitis supurativa. - Google Patents

Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la hidrosadenitis supurativa.

Info

Publication number
MX2024009995A
MX2024009995A MX2024009995A MX2024009995A MX2024009995A MX 2024009995 A MX2024009995 A MX 2024009995A MX 2024009995 A MX2024009995 A MX 2024009995A MX 2024009995 A MX2024009995 A MX 2024009995A MX 2024009995 A MX2024009995 A MX 2024009995A
Authority
MX
Mexico
Prior art keywords
cyano
phenylethyl
hidradenitis suppurativa
oxazepane
carboxamides
Prior art date
Application number
MX2024009995A
Other languages
English (en)
Spanish (es)
Inventor
Ariel Teper
Christina Ramirez
Andrea Maes
Marcela Vergara
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of MX2024009995A publication Critical patent/MX2024009995A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024009995A 2022-02-16 2023-02-16 Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la hidrosadenitis supurativa. MX2024009995A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263310751P 2022-02-16 2022-02-16
PCT/US2023/062731 WO2023159120A1 (en) 2022-02-16 2023-02-16 Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
MX2024009995A true MX2024009995A (es) 2024-08-22

Family

ID=87579133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009995A MX2024009995A (es) 2022-02-16 2023-02-16 Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la hidrosadenitis supurativa.

Country Status (11)

Country Link
US (1) US20250144116A1 (enExample)
EP (1) EP4479059A4 (enExample)
JP (1) JP2025508359A (enExample)
KR (1) KR20240148350A (enExample)
CN (1) CN118695864A (enExample)
AU (1) AU2023221393A1 (enExample)
CA (1) CA3244131A1 (enExample)
GB (1) GB2630719A (enExample)
IL (1) IL314769A (enExample)
MX (1) MX2024009995A (enExample)
WO (1) WO2023159120A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
PT3758708T (pt) 2018-03-01 2025-02-13 Astrazeneca Ab Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) * 2014-01-24 2018-02-24
WO2018022978A1 (en) * 2016-07-29 2018-02-01 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
EP3749326A4 (en) * 2018-02-07 2021-11-03 Insmed Incorporated CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA
EP4252844A3 (en) * 2019-04-17 2023-12-06 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
WO2024026433A2 (en) * 2022-07-28 2024-02-01 Insmed Incorporated Novel dpp1 inhibitors and uses thereof

Also Published As

Publication number Publication date
CA3244131A1 (en) 2023-08-24
EP4479059A4 (en) 2026-01-28
GB202412566D0 (en) 2024-10-09
WO2023159120A1 (en) 2023-08-24
AU2023221393A1 (en) 2024-08-15
KR20240148350A (ko) 2024-10-11
JP2025508359A (ja) 2025-03-26
US20250144116A1 (en) 2025-05-08
GB2630719A (en) 2024-12-04
EP4479059A1 (en) 2024-12-25
IL314769A (en) 2024-10-01
CN118695864A (zh) 2024-09-24

Similar Documents

Publication Publication Date Title
MX2024005126A (es) Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la rinosinusitis cronica.
BR112022011421A2 (pt) Inibidores da proteína mutante kras
MX2024002538A (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.
CO2026002343A2 (es) Inhibidores de pi3k
ES2621140T3 (es) Compuestos ácido acilamino y preparaciones alimenticias que los contienen
UY39029A (es) Uso de compuestos de aminopropionato sustituido en el tratamiento de la infección por sars-cov-2
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
MX2024002885A (es) Inhibidor de la proteasa 3clpro.
PE20220016A1 (es) Inhibidores y metodos de uso de kcnt1
PE20020693A1 (es) Agonistas del receptor alfa activado del proliferador de peroxisomas
UY28674A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
MX2025003008A (es) Regimen de dosificacion para el tratamiento de la pku con un inhibidor de la funcion de slc6a19 como piperidina
PE20161218A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
SE0301888D0 (sv) New use VII
AR047085A1 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
ECSP088965A (es) Derivados de 2-tioxantina que actúan como inhibidores de la mpo
CL2022003511A1 (es) Inhibidores de alk2 para el tratamiento de la anemia.
MX2024009158A (es) Inhibidores de parp7.
UY31385A1 (es) Composicion farmacéutica de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida
CL2022001353A1 (es) Inhibidores de egfr
PE20190106A1 (es) Inhibidores del potenciador del homologo zeste 2
BR112021002565A8 (pt) Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto
MX2024005453A (es) Composiciones y tratamientos con nirogacestat.